PLB-002 / Primelink Bio - LARVOL DELTA

A Study of PLB-002 in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=100 | Recruiting | Sponsor: Primelink BioTherapeitics(ShenZhen) Limited | Not yet recruiting ➔ Recruiting

Enrollment open • Platinum resistant • Hepatocellular Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Testicular Cancer • CLDN6

A Study of PLB-002 in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=100 | Not yet recruiting | Sponsor: Primelink BioTherapeitics(ShenZhen) Limited

New P1 trial • Solid Tumor

PLB-002 is a novel Claudin 6 antibody-drug conjugate for ovarian cancer and testicular germ cell cancer (AACR 2025) - "Here, we describe the development and preclinical characterization of a novel ADC called PLB-002, which consists of a highly selective CLDN6 targeting antibody, PLB-002-ab7, conjugated to a FDA-approved microtubule inhibitor, eribulin, via a Primelink Biotherapeutics proprietary enzyme-cleavable linker with an optimized average drug-to-antibody ratio (DAR) of 4.0. These results show that PLB-002 has remarkable antitumor activity and support the clinical development as a therapeutic ADC for the treatment of ovarian cancer and other CLDN6 expressing solid cancer.*, Equal contributions."

Genito-urinary Cancer • Germ Cell Tumors • Oncology • Ovarian Cancer • Solid Tumor • Testicular Cancer • CLDN3 • CLDN4 • CLDN6